| Literature DB >> 34943729 |
Stephanie Leigh-de Rapper1, Alvaro Viljoen2,3, Sandy van Vuuren1.
Abstract
This study investigated the potential efficacy of 369 commercial essential oil combinations for antimicrobial, anti-toxic and anti-inflammatory activity with the aim of identifying synergy among essential oils commonly used in combination by aromatherapists for respiratory purposes. Essential oil combinations were assessed for their antimicrobial activities using a panel of Gram-positive, Gram-negative, and yeast strains associated with respiratory tract infections. The antimicrobial activity was measured by determining the minimal inhibitory concentration (MIC) of microbial growth. The fractional inhibitory concentration index (ΣFIC) was calculated to determine the antimicrobial interactions between the essential oils in the combination. The toxicity of the essential oil combinations was tested in vitro using the brine shrimp lethality assay, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on RAW 264.7 mouse macrophage cells and A549 lung cancer cell lines. In addition, an inflammatory response was evaluated measuring nitric oxide production. The essential oils, when in combination, demonstrated an increased antimicrobial effect, a reduction in toxicity and provided improved anti-inflammatory outcomes. Five distinct combinations [Cupressus sempervirens (cypress) in combination with Melaleuca alternifolia (tea tree), Hyssopus officinalis (hyssop) in combination with Rosmarinus officinalis (rosemary), Origanum marjorana (marjoram) in combination with M. alternifolia, Myrtus communis (myrtle) in combination with M. alternifolia and Origanum vulgare (origanum) in combination with M. alternifolia] were found to be the most promising, demonstrating antimicrobial activity, reduced cytotoxicity and improved anti-inflammatory effects. With the increased prevalence of respiratory tract infections and the growing antimicrobial resistance development associated with antimicrobial treatments, this study provides a promising complementary alternative for the appropriate use of a selection of essential oil combinations for use in the respiratory tract.Entities:
Keywords: anti-inflammatory; antimicrobial; combinations; essential oils; inhalation; respiratory tract; synergy; toxicity
Year: 2021 PMID: 34943729 PMCID: PMC8698682 DOI: 10.3390/antibiotics10121517
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Summary of noteworthy essential oil antimicrobial activity alone (a) and when in combination (b).
The mean MIC (n = 3) with standard deviation in brackets and ΣFIC values of the essential oil combinations investigated against pathogens of the respiratory tract.
| Essential Oil Combinations | Mean MIC Value (mg/mL) ( | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |||||||||||
| (ATCC 25924) | (ATCC 55618) | (ATCC 49619) | (ATCC 12344) | (ATCC 19420) | (ATCC 19418) | (ATCC 13883) | (ATCC 23246) | (ATCC 14116) | |||||||||||
| Essential Oil 1 | Essential Oil 2 | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** | MIC * | ƩFIC ** |
|
|
|
|
|
| 3.09 |
|
| 2.00 (±0.00) | 1.25 |
|
| 1.50 (±0.71) |
|
|
|
| 1.17 | ||
|
|
|
| 1.25 | 2.00 (±0.00) |
|
| 1.69 |
|
| 2.00 (±0.00) | 1.67 |
|
| 2.00 (±0.00) | 2.50 |
|
| ||
|
|
|
|
|
|
|
|
| 4.00 (±0.00) | 2.00 |
|
|
|
| 2.00 (±0.00) | 3.00 |
|
| ||
| 4.00 (±0.00) |
| 2.00 (±0.00) |
|
|
| 6.00 (±2.83) | 2.00 |
|
| 1.50 (±0.71) |
| 2.00 (±0.00) |
| 2.00 (±0.00) |
|
| 1.50 | ||
| 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
| 8.00 (±0.00) | 5.33 | 2.00 (±0.00) |
|
|
|
|
|
|
| 1.50 (±0.71) | 3.75 | ||
|
|
|
|
|
|
|
| 1.55 | 2.00 (±0.00) | 1.58 |
| 2.03 | 4.00 (±0.00) |
|
| 2.50 |
|
| ||
|
|
|
|
|
|
|
| 1.50 |
|
|
|
|
| 1.50 | 2.00 (±0.00) | 2.67 |
| 2.08 | ||
| 2.00 (±0.00) |
| 2.00 (±0.00) |
|
|
| 1.50 (±0.71) |
| 1.50 (±0.71) |
| 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
|
| 2.50 | ||
| 2.00 (±0.00) | 1.33 | 2.00 (±0.00) |
| 1.50 (±0.71) |
| 8.00 (±0.00) | 2.33 | 2.00 (±0.00) |
| 4.00 (±0.00) | 1.33 |
|
| 2.00 (±0.00) |
|
|
| ||
| 4.00 (±0.00) | 1.17 |
|
| 2.00 (±0.00) |
| 1.50 (±0.71) |
|
|
| 3.00 (±1.41) | 1.50 | 4.00 (±0.00) | 1.50 | 2.00 (±0.00) |
|
|
| ||
| 2.00 (±0.00) |
| 2.00 (±0.00) |
| 2.00 (±0.00) |
| 4.00 (±0.00) | 1.33 | 2.00 (±0.00) |
| 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
|
| 1.25 | ||
|
|
|
|
|
|
|
| 1.69 |
|
|
|
|
| 1.50 | 2.00 (±0.00) | 1.17 |
| 2.04 | ||
|
|
|
|
| 2.00 (±0.00) | 1.67 |
|
|
|
| 3.00 (±1.41) | 1.50 | 8.00 (±0.00) | 2.50 | 2.00 (±0.00) |
|
|
| ||
| 2.00 (±0.00) | 1.33 | 2.00 (±0.00) | 1.50 | 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
| 8.00 (±0.00) | 1.83 |
|
| 2.00 (±0.00) | 1.50 |
|
| ||
| 2.00 (±0.00) | 1.25 |
|
| 2.00 (±0.00) | 1.50 |
|
| 2.00 (±0.00) |
|
|
|
|
| 3.00 (±1.41) | 1.75 |
| 1.69 | ||
|
|
|
|
| 2.00 (±0.00) | 1.17 |
|
| 2.00 (±0.00) |
| 6.00 (±2.83) | 1.50 |
|
| 2.00 (±0.00) | 1.67 |
| 2.17 | ||
| 2.00 (±0.00) |
| 2.00 (±0.00) |
| 3.00 (±1.41) | 1.50 |
|
| 1.50 (±0.71) |
| 4.00 (±0.00) |
| 4.00 (±0.00) | 2.00 | 2.00 (±0.00) |
|
|
| ||
|
|
| 4.00 (±0.00) | 2.00 | 8.00 (±0.00) | 3.67 |
|
| 2.00 (±0.00) |
|
|
|
|
| 2.00 (±0.00) |
|
|
| ||
| 3.00 (±1.41) | 1.88 | 2.00 (±0.00) |
| 2.00 (±0.00) | 1.50 | 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
|
|
| 2.00 (±0.00) |
|
|
| ||
| 2.00 (±0.00) |
|
|
|
|
| 2.00 (±0.00) |
| 2.00 (±0.00) |
| 4.00 (±0.00) | 1.67 |
|
|
|
|
|
| ||
|
| 1.13 | 2.00 (±0.00) | 1.67 | 2.00 (±0.00) |
|
|
|
|
|
|
| 1.50 (±0.71) |
| 2.00 (±0.00) | 1.50 |
|
| ||
| 2.00 (±0.00) |
|
|
| 1.50 (±0.71) |
| 2.00 (±0.00) | 1.67 | 3.00 (±1.41) |
| 4.00 (±0.00) | 2.00 |
|
|
|
|
|
| ||
| 2.00 (±0.00) | 1.25 |
|
|
|
| 2.00 (±0.00) | 1.67 | 2.00 (±0.00) |
| 4.00 (±0.00) | 2.00 |
|
| 3.00 (±1.41) | 1.50 |
|
| ||
| 4.00 (±0.00) | 0.75 | 2.00 (±0.00) | 1.00 | 2.00 (±0.00) | 0.63 | 2.00 (±0.00) | 0.83 | 1.50 (±0.71) |
| 1.50 (±0.71) |
| 8.00 (±0.00) | 2.50 | 2.00 (±0.00) | 0.63 |
| 0.88 | ||
| 8.00 (±0.00) | 1.00 |
|
| 4.00 (±0.00) | 1.25 | 8.00 (±0.00) | 2.67 | 1.50 (±0.71) |
| 1.50 (±0.71) |
| 8.00 (±0.00) | 1.83 | 2.00 (±0.00) |
|
| 0.56 | ||
|
|
| 2.00 (±0.00) | 1.00 | 2.00 (±0.00) | 1.13 | 2.00 (±0.00) | 1.33 | 2.00 (±0.00) | 0.75 | 2.00 (±0.00) | 0.83 | 2.00 (±0.00) | 1.13 | 2.00 (±0.00) | 0.63 |
| 0.81 | ||
|
| 0.63 | 2.00 (±0.00) | 1.00 | 2.00 (±0.00) |
|
| 0.67 |
|
| 2.00 (±0.00) | 1.00 |
| 0.75 | 4.00 (±0.00) | 2.00 |
|
| ||
| 2.00 (±0.00) | 0.75 |
|
|
|
|
| 2.17 | 1.50 (±0.71) | 0.56 |
|
| 2.00 (±0.00) | 1.00 |
|
|
| 1.17 | ||
|
| 0.63 |
|
|
| 0.75 |
| 0.55 |
|
|
| 1.13 |
|
| 2.00 (±0.00) | 2.00 |
| 1.13 | ||
|
|
|
| 0.83 |
| 0.75 |
|
|
|
|
| 1.17 |
|
| 2.00 (±0.00) | 1.50 |
| 0.54 | ||
|
|
|
|
|
|
|
| 1.25 | 4.00 (±0.00) | 1.50 |
| 1.50 |
|
| 2.00 (±0.00) | 2.00 |
| 1.33 | ||
| Positive control (ciprofloxacin) | 0.50 × 10−3 | 0.50 × 10−3 | 0.50 × 10−3 | 0.50 × 10−3 | 0.50 × 10−3 | 0.25 × 10−3 | 1.00 × 10−3 | 0.50 × 10−3 | n.a. | ||||||||||
| Positive control (amphotericin b) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 0.50 × 10−3 | ||||||||||
| Negative control (acetone in water) | >8.00 | >8.00 | >8.00 | >8.00 | >8.00 | >8.00 | >8.00 | >8.00 | >8.00 | ||||||||||
MIC * denotes noteworthy antimicrobial effect (MIC less than or equal to 1 mg/mL); ƩFIC ** in bold and italics denotes synergistic antimicrobial effect (ƩFIC less than or equal to 0.50); while ƩFIC in italics only denotes additive antimicrobial effect (ƩFIC greater than 0.50 and less than or equal to 1.00).
Figure 2Summary of essential oil toxic effects alone (a) and when in combination (b) against brine shrimp.
The mean percentage brine-shrimp viability after 48 h (n = 3) with standard deviation in brackets and ΣFIC values of the essential oil combinations investigated.
| Essential Oil Combinations | Individual Brine-Shrimp | Combined Brine-Shrimp Mortality (%) * | ƩFIC ** | ||
|---|---|---|---|---|---|
| Essential Oil 1 | Essential Oil 2 | Essential Oil 1 | Essential Oil 2 | ||
|
|
|
| 3.16 | ||
|
|
|
|
| ||
|
|
|
| 4.99 | ||
|
|
| 21.29 | |||
|
|
| 8.48 | |||
|
|
| 34.67 | |||
|
|
|
| 1754.74 | ||
|
|
|
| 74.18 | ||
|
|
|
| 1.41 | ||
|
|
| 14.46 | |||
|
|
|
| 10.23 | ||
|
|
|
| 5.06 | ||
|
|
|
| 48.51 | ||
|
|
|
| 1429.46 | ||
|
|
|
| 19.99 | ||
|
|
|
| 11.76 | ||
| 99.67 (±0.57) |
|
| 3.65 | ||
|
|
| 56.47 (±5.09) | 80.06 | ||
|
|
| 128.15 | |||
|
|
| 279.78 | |||
|
|
|
| 12.28 | ||
|
|
| 2.92 | |||
| 99.57 (±0.74) |
|
|
| ||
|
|
|
| |||
|
|
| 3.91 | |||
|
|
|
| |||
| Positive control (Potassium dichromate) | 99.95 (±0.03) | ||||
| Negative control (Sea water) | 0.00 (±0.00) | ||||
| Solvent control (DMSO) | 0.00 (±0.00) | ||||
Brine-shrimp viability (%) * in bold denotes non-toxic effect (% mortality less than 50%); ƩFIC ** in bold denotes synergistic effect (ƩFIC less than or equal to 0.50) and ƩFIC in italics denotes additive effect (ƩFIC greater than 0.50 and less than or equal to 1.00).
Figure 3Summary of essential oil anti-inflammatory effects alone (a) and when in combination (b).
The mean percentage NO production of RAW 264.7 macrophages (n = 3) with standard deviation in brackets and ΣFIC values after treatment with essential oil combinations.
| Essential Oil Combination | Individual Essential Oil Nitrite Production (μM) | Combined Essential Oils Nitrite Production (μM) * | ƩFIC *** % NO Production | ||
|---|---|---|---|---|---|
| Essential Oil 1 | Essential Oil 2 | Essential oil 1 | Essential oil 2 | ||
| 1.95 (±0.02) | 2.45 (±0.07) |
| 1.02 | ||
| 2.91 (±0.19) | 4.06 (±0.23) | 3.83 (±0.10) | 1.13 | ||
| 5.43 (±0.38) | 4.57 (±0.19) | 4.04 (±0.05) |
| ||
| 2.45 (±0.07) | 6.38 (±0.44) | 3.75 (±0.05) | 1.06 | ||
| 2.45 (±0.07) | 4.71 (±0.40) |
|
| ||
| 2.17 (±0.10) | 2.02 (±0.10) |
|
| ||
| 2.12 (±0.06) | 1.93 (±0.02) |
|
| ||
| 2.02 (±0.02) | 2.17 (±0.10) |
|
| ||
| 2.02 (±0.02) | 3.61 (±0.05) | 4.30 (±0.05) | 1.66 | ||
| 2.02 (±0.02) | 2.00 (±0.02) |
| 1.00 | ||
| 1.95 (±0.02) | 3.38 (±0.02) |
|
| ||
| 1.95 (±0.02) | 4.06 (±0.23) |
|
| ||
| 2.02 (±0.10) | 2.02 (±0.02) |
|
| ||
| 2.02 (±0.10) | 3.59 (±0.07) |
|
| ||
| 2.02 (±0.10) | 2.99 (±0.38) |
|
| ||
| 2.02 (±0.10) | 4.06 (±0.23) | 3.49 (±0.02) | 1.30 | ||
| 1.99 (±0.03) | 2.85 (±0.04) |
| 1.00 | ||
| 3.59 (±0.07) | 4.73 (±0.18) | 3.54 (±0.03) |
| ||
| 2.06 (±0.02) | 2.99 (±0.04) |
|
| ||
| 2.06 (±0.02) | 4.68 (±0.17) | 3.44 (±0.18) | 1.20 | ||
| 2.99 (±0.04) | 2.00 (±0.02) |
| 1.24 | ||
| 4.81 (±0.11) | 4.06 (±0.23) | 3.05 (±0.14) |
| ||
| 3.07 (±0.13) | 4.06 (±0.23) |
|
| ||
| 4.88 (±0.47) | 4.06 (±0.23) | 3.87 (±0.18) |
| ||
| Medium only | 1.77 (±4.52) | ||||
| Positive control (LPS + Aminoguanidine) | 2.58 (±2.39) | ||||
| Negative control (LPS + medium) | 4.90 (±9.21) | ||||
Combined essential oil NO production (%) * bold and in italics denotes anti-inflammatory effect (μM less than 2.97); ƩFIC *** in bold denotes synergistic effect (ƩFIC less than or equal to 0.50); ƩFIC in italics denotes additive effect (ƩFIC greater than 0.50 but less than or equal to 1.00).
The mean percentage cell viability of RAW 264.7 macrophages (n = 3) with standard deviation in brackets and ΣFIC values after treatment with essential oil combinations.
| Essential Oil Combination | Cell Viability against | Cell Viability against Combined | ƩFIC *** | ||
|---|---|---|---|---|---|
| Essential Oil 1 | Essential Oil 2 | Essential Oil 1 | Essential Oil 2 | ||
| 8.11 (±4.52) | 47.98 (±0.08) | 7.90 (±4.05) |
| ||
| 50.63 (±2.39) | 66.15 (±2.07) |
| 1.16 | ||
| 58.49 (±9.20) | 67.01 (±0.23) |
| 1.2 | ||
| 47.98 (±0.08) | 61.83 (±3.25) | 58.45 (±0.09) | 1.08 | ||
| 60.04 (±3.54) | 36.90 (±1.75) |
| |||
| 33.40 (±4.98) | 7.98 (±0.33) | 8.68 (±2.65) |
| ||
| 8.11 (±3.77) | 9.12 (±5.27) | 8.11 (±2.65) |
| ||
| 14.99 (±0.15) | 33.40 (±4.98) | 8.07 (±0.88) |
| ||
| 71.04 (±0.15) | 55.64 (±0.69) | 2.25 | |||
| 12.3 (±4.82) | 8.15 (±0.15) |
| |||
| 23.83 (±3.70) | 57.68 (±3.99) | 7.98 (±0.09) |
| ||
| 66.15 (±2.07) | 51.65 (±0.23) | 1.47 | |||
| 7.98 (±0.33) | 14.99 (±0.15) | 9.94 (±0.23) |
| ||
| 63.14 (±0.09) | 12.18 (±0.13) |
| |||
| 71.53 (±3.44) | 9.08 (±0.23) |
| |||
| 66.15 (±2.07) |
| 5.88 | |||
| 8.07 (±5.13) | 8.11 (±1.63) | 8.07 (±1.74) |
| ||
| 63.14 (±0.09) | 77.64 (±0.84) |
| 1.14 | ||
| 7.94 (±0.09) | 71.53 (±3.44) | 8.27 (±0.48) |
| ||
| 68.92 (±0.08) |
| 5.06 | |||
| 71.53 (±3.44) | 12.3 (±4.82) |
| 3.28 | ||
| 57.84 (±0.28) | 66.15 (±2.07) |
| 1.46 | ||
| 59.43 (±4.00) |
| 1.25 | |||
| 68.84 (±3.69) |
| 1.28 | |||
| LPS | 109.31 (±0.04) | ||||
| Positive control (Adenosine Guanine) | 119.51 (±0.23) | ||||
| Negative control (LPS + medium) | 100.00 (±0.18) | ||||
Combined essential oil cell viability (%) ** bold and italics denotes non-toxic effect (%cell viability greater than 50%); ƩFIC *** in bold denotes synergistic effect (ƩFIC less than or equal to 0.50); ƩFIC in italics denotes additive effect (ƩFIC greater than 0.50 but less than or equal to 1.00).
The mean percentage cell viability of A549 lung cancer cell line (n = 3) with standard deviation in brackets and ΣFIC values after treatment with essential oil combinations.
| Essential Oil Combination | A549 Cell Viability * Following Individual Essential Oils (%) | A549 Cell Viability * Following Combined Essential Oils | ƩFIC | ||
|---|---|---|---|---|---|
| Essential Oil 1 | Essential Oil 2 | Essential Oil 1 | Essential Oil 2 | ||
|
|
|
|
| ||
|
|
|
|
| ||
|
|
|
| 1.02 | ||
|
|
|
| 1.02 | ||
|
|
|
| |||
|
|
|
|
| ||
|
|
|
|
| ||
|
|
|
|
| ||
|
|
|
| |||
|
|
|
| |||
|
|
|
| |||
|
|
|
| 1.02 | ||
|
|
|
| |||
|
|
|
|
| ||
|
|
| 1.02 | |||
|
|
|
| |||
|
|
|
| |||
|
|
|
| 1.02 | ||
|
|
|
| 1.06 | ||
|
|
|
|
| ||
|
|
|
| |||
|
|
|
|
| ||
|
|
|
|
| ||
|
|
|
| |||
|
|
| 1.01 | |||
| Positive control (Melphalan) | 66.37 (±0.26) | ||||
| Negative control (Medium control) | 92.30 (±0.27) | ||||
A549 cell viability (%) * denotes non-toxic effects (% cell viability greater than 50%); ƩFIC ** in bold denotes synergistic effect (ƩFIC less than or equal to 0.50); ƩFIC in italics denotes additive effect (ƩFIC greater than 0.50 but less than or equal to 1.00).
Figure 4Summary of study workflow.